StudyFinder

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Recruiting

This study uses different drug combinations to treat women who have endometrial cancer that has come back or has not responded to treatment. The drugs have different ways of stopping the growth of tumor cells and we are looking to see if different combinations are more effective.

I'm interested

Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments
• following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.); NOTE: clear cell histology is excluded
• must have had one prior chemotherapeutic regimen for management of endometrial carcinoma
• Body weight > 30 kg
• able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption
Exclusion Criteria:

• Prior enrollment into a clinical trial including cediranib or olaparib; Note: prior bevacizumab is not an exclusion criterion
• Pregnant women are excluded

Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspirate, Procedure: Bone Marrow Biopsy, Drug: Capivasertib, Drug: Cediranib, Drug: Cediranib Maleate, Procedure: Computed Tomography, Biological: Durvalumab, Procedure: Echocardiography, Procedure: Multigated Acquisition Scan, Drug: Olaparib

Cancer

Endometrial Cancer

Kristen Nelson - knelso65@fairview.org
Edward Greeno, M.D.
PHASE2
MMCORC011
See this study on ClinicalTrials.gov

Back